Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 68.1 TWD -2.44% Market Closed
Market Cap: 11.2B TWD
Have any thoughts about
Tanvex BioPharma Inc?
Write Note

Net Margin
Tanvex BioPharma Inc

-5 232.6%
Current
-74 446.5%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-5 232.6%
=
Net Income
-1.8B
/
Revenue
34.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
KY
Tanvex BioPharma Inc
TWSE:6541
11.2B TWD
-5 233%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
9%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
133.6B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.8B EUR
-14%
Country KY
Market Cap 11.2B TWD
Net Margin
-5 233%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 312.7B USD
Net Margin
9%
Country US
Market Cap 158.3B USD
Net Margin
13%
Country US
Market Cap 116.2B USD
Net Margin
-5%
Country US
Market Cap 112.4B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 133.6B AUD
Net Margin
18%
Country US
Market Cap 81.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.8B EUR
Net Margin
-14%
No Stocks Found

Tanvex BioPharma Inc
Glance View

Market Cap
11.2B TWD
Industry
Biotechnology

Tanvex BioPharma, Inc. operates as clinical stage company, which engages in the research and development, production, and sale of pharmaceutical products. The firm is also engaged in areas of strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing and warehousing, sales and distribution. The Company’s product pipeline includes Neupogen (TX-01), TX-05, TX-04, TX-16, TX-52, and others. The firm offers a vertically integrated manufacturing platform for biopharmaceuticals. By controlling the entire process from research and development (R&D) and cell-line development. The firm is developing and delivering biologic and biosimilar drugs to the people.

Intrinsic Value
1.61 TWD
Overvaluation 98%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-5 232.6%
=
Net Income
-1.8B
/
Revenue
34.6m
What is the Net Margin of Tanvex BioPharma Inc?

Based on Tanvex BioPharma Inc's most recent financial statements, the company has Net Margin of -5 232.6%.